TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9146770

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 60 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Number of subjects: 163
Study: 7711430

Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 and interferon-alpha 2b (rIL-2 and IFN-alpha 2b) administered subcutaneously for 6 weeks (3 treatment cycles, each with 3 weeks of administration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dacarbazine in addition to rIL-2 and IFN-alpha 2b
Number of subjects: 30
Study: 3330985

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, twice daily; n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol or alphamethyldopa (n = 7)
Number of subjects: 14
Study: 31814488

Group type: COMPARATOR
Intervention: 30mg MDMA
Number of subjects: 13

Group type: COMPARATOR
Intervention: 70mg MDMA
Number of subjects: 13
Study: 29186562

Group type: EXPERIMENTAL
Intervention: REACH for Control (RFC) plus standard medical care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (SC) only
Number of subjects: 50
Study: 28303642

Group type: EXPERIMENTAL
Intervention: Collagen matrix seal (CMS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Collagen sponge (CS)
Number of subjects: 28
Study: 25960401

Group type: EXPERIMENTAL
Intervention: Length of stay (LOS) ≥14 days
Number of subjects: 4020

Group type: COMPARATOR
Intervention: Length of stay (LOS) ≤3 days
Number of subjects: 4020
Study: 24048467

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 2293

Group type: COMPARATOR
Intervention: CHADS2 score
Number of subjects: 2293

Group type: COMPARATOR
Intervention: CHA2DS2-VASc score
Number of subjects: 2293
Study: 21161185

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 19217154

Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg or 63 mg) every week for 4 weeks (weeks 0-3)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Ustekinumab (63 mg) at weeks 12 and 16
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg or 63 mg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 146
Study: 16708768

Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum (GP) extraction 80 mL for 4 months after 2 months of controlled diet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo capsule for 4 months after 2 months of controlled diet
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups followed a controlled diet for 2 months
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups measured for uric acid levels from month 2 to month 6
Number of subjects: 56
Study: 15636412

Group type: EXPERIMENTAL
Intervention: Multicomponent treatment intervention (MTI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 42
Study: 11206682

Group type: EXPERIMENTAL
Intervention: Benidipine (6 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Benidipine (6 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nifedipine (6 weeks)
Number of subjects: 43
Study: 9028542

Group type: EXPERIMENTAL
Intervention: Premenopausal females (mean age for menopause - 2 SD to + 2 SD, 43-57 years)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Postmenopausal females (mean age for menopause - 2 SD to + 2 SD, 43-57 years)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Spine BMD in premenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Spine BMD in postmenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Femoral neck BMD in premenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Femoral neck BMD in postmenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Trochanter BMD in premenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Trochanter BMD in postmenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Ward's triangle BMD in premenopausal females
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Ward's triangle BMD in postmenopausal females
Number of subjects: 429
Study: 8280541

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 100

Group type: COMPARATOR
Intervention: No cricoid pressure
Number of subjects: 100
Study: 3566867

Group type: EXPERIMENTAL
Intervention: Fe (III)‐hydroxide‐polymaltose complex
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fe (II)‐ascorbate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fe (III)‐hydroxide‐polymaltose complex with test meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fe (III)‐complex
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fe (II)‐sulphate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 16
Study: 2661734

Group type: EXPERIMENTAL
Intervention: CMFPT (cyclophosphamide, methotrexate, fluorouracil, prednisone plus tamoxifen)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, methotrexate, fluorouracil, prednisone)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: CMFP (+/‐ T)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 265

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 265
Study: 30298463

Group type: EXPERIMENTAL
Intervention: Narrow temporal window (TW) for simultaneous perception as measured by a temporal order judgement task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced ability to engage in multisensory integration during the sound-induced flash illusion task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrow TW
Number of subjects: 0
Study: 31368422

Group type: EXPERIMENTAL
Intervention: High-Ca fat-free milk (HC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-Ca control diet (LC)
Number of subjects: 14
Study: 27830294

Group type: EXPERIMENTAL
Intervention: Mutant L205A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type ChKRED20
Number of subjects: 0
Study: 26002690

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 23337646

Group type: EXPERIMENTAL
Intervention: Alginate dressing and polyurethane film
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonadherent paraffin gauze
Number of subjects: 30
Study: 21708003

Group type: EXPERIMENTAL
Intervention: My PKU web page with access to blood Phe values
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual procedure (phone call or e-mail by a dietician)
Number of subjects: 38
Study: 19621425

Group type: EXPERIMENTAL
Intervention: GST‐M1 null genotype
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GST‐M1 normal genotype
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GST‐M1 genotype
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ABCB1 C3435T genotype
Number of subjects: 36
Study: 16671836

Group type: EXPERIMENTAL
Intervention: Musical story
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Spoken story
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care/control
Number of subjects: 64
Study: 15544589

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Rhinitis QOL Questionnaire (RQLQ)
Number of subjects: 224
Study: 11422765

Group type: EXPERIMENTAL
Intervention: Parenteral iron administration (iron dextran 100 mg at ten consecutive dialysis sessions)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No parenteral iron administration
Number of subjects: 208
Study: 9404740

Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation (NPV) by a poncho-wrap ventilator
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (spontaneous assisted ventilation)
Number of subjects: 27
Study: 8501147

Group type: EXPERIMENTAL
Intervention: 5 IU GH (iv infusion)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 5 IU GH (im bolus injection)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 48 IU GH (iv infusion)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30 micrograms/h GHRH (iv infusion)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3125077

Group type: EXPERIMENTAL
Intervention: Enterococcus lactic acid bacteria strain SF68 (two capsules three times daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactulose (30 ml four times daily)
Number of subjects: 40
Study: 29525739

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 111
Study: 26717867

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) pre-operatively for CAS
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) post-operatively for CAS
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) pre-operatively for CEA
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) post-operatively for CEA
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mono antiplatelet therapy (MAPT) post-procedural
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Testing for antiplatelet therapy resistance
Number of subjects: 77
Study: 24515619

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 66
Study: 22810570

Group type: EXPERIMENTAL
Intervention: Sugar substitute products
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional sugar
Number of subjects: 60
Study: 20919760

Group type: EXPERIMENTAL
Intervention: Treatment Advocacy Program (TAP)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 313
Study: 17498071

Group type: EXPERIMENTAL
Intervention: Reformulated BeneFix
Number of subjects: 17
Study: 16313478

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-oestradiol plus 1 mg DRSP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-oestradiol plus 2 mg DRSP
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta-oestradiol plus 3 mg DRSP
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 12484506

Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus spironolactone (25 mg) for 60 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: ACE inhibitor alone for 60 weeks
Number of subjects: 20
Study: 10716206

Group type: EXPERIMENTAL
Intervention: Colour flicker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luminance flicker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coloured objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grey-scaled objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coloured flicker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chromatic flicker
Number of subjects: 0
Study: 7590617

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg given at 11:00 p.m. on on-call night
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dexamethasone 1 mg given at 11:00 p.m. on control night
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: On-call night
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control night
Number of subjects: 42
Study: 2075246

Group type: EXPERIMENTAL
Intervention: Gemeprost (16,16 dimethyl-PGE1-methyl ester) pessaries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-amniotic PGF2 alpha combined with hypertonic saline, intravenous oxytocin, and a hygroscopic cervical dilator (Dilapan)
Number of subjects: 0
Study: 6115654

Group type: EXPERIMENTAL
Intervention: bunitrolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 30407895

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 23
Study: 29871023

Group type: EXPERIMENTAL
Intervention: Adjunctive homeopathy
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 612
Study: 27290985

Group type: EXPERIMENTAL
Intervention: RSGB group (lidocaine 1% 7 ml under ultrasound guidance)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 80
Study: 24898466

Group type: EXPERIMENTAL
Intervention: Body-centered meditation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional morning walk
Number of subjects: 44
Study: 21551421

Group type: EXPERIMENTAL
Intervention: PILI Lifestyle Program (PLP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard Behavioral Program (SBP)
Number of subjects: 144
Study: 19222821

Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT) before treatment decision
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Clinical management (presumptive treatment)
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: RDT positive patients (rainy season)
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: RDT negative patients (rainy season)
Number of subjects: 2169
Study: 17785084

Group type: EXPERIMENTAL
Intervention: Low current group (Group A, n = 118)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Regular current group (Group B, n = 70)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Posterior subgroup of Group A
Number of subjects: 188

Group type: COMPARATOR
Intervention: Posterior subgroup of Group B
Number of subjects: 188
Study: 15123534

Group type: EXPERIMENTAL
Intervention: LVAD placement
Number of subjects: 129

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 129
Study: 11593318

Group type: EXPERIMENTAL
Intervention: TBI/CY/E
Number of subjects: 351

Group type: COMPARATOR
Intervention: Bu/Mel/T
Number of subjects: 351

Group type: COMPARATOR
Intervention: Bu/Mel/T (for patients with prior dose-limiting radiation)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: TBI/CY/E and Bu/Mel/T
Number of subjects: 351
Study: 9828916

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) replacement therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8106787

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 48 h)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Chloroquine plus Clindamycin (5 mg/kg every 12 h for 6 doses)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Quinine (12 mg/kg every 12 h for 6 doses)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Quinine plus Clindamycin (5 mg/kg every 12 h for 6 doses)
Number of subjects: 130
Study: 2631854

Group type: EXPERIMENTAL
Intervention: Preparation A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preparation B
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preparation C
Number of subjects: 12
Study: 1139857

Group type: EXPERIMENTAL
Intervention: Commercial carbamazepine tablets
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propylene glycol solution
Number of subjects: 6
Study: 31691831

Group type: EXPERIMENTAL
Intervention: Acoustic tones delivered on the up phase of the slow-wave (STIM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inaudible 'tones' during equivalent periods of stimulation (SHAM)
Number of subjects: 24
Study: 31118491

Group type: EXPERIMENTAL
Intervention: Low-dose helical CT (LDCT) screening
Number of subjects: 0
Study: 29219126

Group type: EXPERIMENTAL
Intervention: Nutritious meals provided through centralized kitchens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular meals from control kitchens
Number of subjects: 0
Study: 26068624

Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL) procedure
Number of subjects: 206

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 206
Study: 23601084

Group type: EXPERIMENTAL
Intervention: TM38837 500 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TM38837 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rimonabant 60 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21757931

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60
Study: 19369137

Group type: EXPERIMENTAL
Intervention: Intervention group (morning shift, individualized vaccination with reference nurse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (afternoon shift, vaccination as in previous years)
Number of subjects: 0
Study: 16364329

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15605935

Group type: EXPERIMENTAL
Intervention: Pneumatic leg brace
Number of subjects: 31
Study: 11318504

Group type: EXPERIMENTAL
Intervention: Mixture of palm and soybean oils (PS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palmstearin and soybean oils (PSS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palm oil (P)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palmolein and soybean oils (POS)
Number of subjects: 10
Study: 9209174

Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil (9 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vegetable oil (safflower oil)
Number of subjects: 0
Study: 7758184

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (untrained group)
Number of subjects: 55
Study: 2225519

Group type: EXPERIMENTAL
Intervention: Fundus body positioning of pH electrode
Number of subjects: 22

Group type: COMPARATOR
Intervention: Identical diet on two different days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Variations of carbohydrate, protein, and fat content of isocaloric meals
Number of subjects: 22
Study: 453272

Group type: EXPERIMENTAL
Intervention: Amniocentesis
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oxytocin challenge tests (OCT's)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Induction of labor after discovery of meconium
Number of subjects: 180
Study: 31420830

Group type: EXPERIMENTAL
Intervention: metabolic gastric bypass (mRYGB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: sleeve gastrectomy (SG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: greater curvature plication (GCP)
Number of subjects: 45
Study: 30928162

Group type: EXPERIMENTAL
Intervention: Screening Arm (SA)
Number of subjects: 14136

Group type: COMPARATOR
Intervention: Control Arm (CA)
Number of subjects: 14136
Study: 28922651

Group type: EXPERIMENTAL
Intervention: Nicotine patch + nicotine lozenge
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Bupropion + nicotine lozenge
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 1504

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1504
Study: 28671098

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted approach
Number of subjects: 246

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 246
Study: 23674879

Group type: EXPERIMENTAL
Intervention: Medical adhesive spray (group A)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Routine wound management (group B)
Number of subjects: 171
Study: 21852283

Group type: EXPERIMENTAL
Intervention: Telephone-Linked Computer-based Long-term Interactive Fitness Trainer (n = 52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Attention control (n = 51)
Number of subjects: 103
Study: 19151274

Group type: EXPERIMENTAL
Intervention: Indicated preoperative testing (complete blood count, electrolytes, blood glucose, creatinine, electrocardiogram, chest radiograph)
Number of subjects: 1061

Group type: COMPARATOR
Intervention: No preoperative testing
Number of subjects: 1061
Study: 15519184

Group type: EXPERIMENTAL
Intervention: Carmeda-coated oxygenators (BPS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenators (BAS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-coated oxygenators (UMS)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All groups (UMS, BPS, BAS)
Number of subjects: 71
Study: 11343664

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin, enoxaparin, or reviparin for at least 4 days, plus a coumarin derivative with a target INR of 2.0 to 3.0 starting on the 1st or 2nd day of treatment.
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Iliofemoral vein thrombosis
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 1149
Study: 8860284

Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 22
Study: 1495357

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin/5-FU) followed by definitive radiation (6600 to 7600 cGy)
Number of subjects: 46
Study: 6439026

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pasteurized yogurt
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cultured milk (buttermilk)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sweet acidophilus milk
Number of subjects: 9
Study: 31174584

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 168

Group type: COMPARATOR
Intervention: NSAIDs (historical cohort)
Number of subjects: 168
Study: 29797908

Group type: EXPERIMENTAL
Intervention: Governor vessel daoqi method of acupuncture combined with estazolam (2 mg, taken 30 min before sleeping)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Estazolam alone (2 mg, taken 30 min before sleeping)
Number of subjects: 70
Study: 27075687

Group type: EXPERIMENTAL
Intervention: Daytime transcutaneous electrical stimulation of the genioglossus muscle
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard continuous positive airway pressure (CPAP) therapy
Number of subjects: 38
Study: 24132806

Group type: EXPERIMENTAL
Intervention: Video-laryngoscopy using a custom device (USB endoscopic camera, Macintosh laryngoscope blade, personal computer)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Video-laryngoscopy using a custom device
Number of subjects: 24
Study: 22674708

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Orthopaedic consultation
Number of subjects: 553

Group type: COMPARATOR
Intervention: Waiting time characteristics
Number of subjects: 553